1-4 of 4
Frank C. Passero, Jr., MD
Close
Sort by
Journal Articles

Proteasome and HDAC Inhibitor Therapy in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Nuclear Factor Erythroid 2 like 2 (NRF2)-Dependent Cell Death and Function

Frank C. Passero, Jr., MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, J. Tyson McDonald, PhD, Andrew M Evens, DO, MSc, FACP
Journal: Blood
Blood (2016) 128 (22): 3020.
https://doi.org/10.1182/blood.V128.22.3020.3020
Published: 2016
Journal Articles

CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL)

Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Saheli Sarkar, PhD, Pooja Sabhachandani, Frank C. Passero, Jr., MD, Sneha Purvey, MD, Laurent Boissel, PhD, Tania Konry, Andrew M Evens, DO, MSc, FACP
Journal: Blood
Blood (2016) 128 (22): 4174.
https://doi.org/10.1182/blood.V128.22.4174.4174
Published: 2016
Journal Articles

The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach

Frank C. Passero, Jr., MD, Ravi Dashnamoorthy, PhD, Afshin Beheshti, PhD, Lynn Hlatky, PhD, Nassera Abermil, MS, PharmD, Michael E Coyle, MD, Jaya Sharma, MD MBBS, Andrew M. Evens, DO, MSc
Journal: Blood
Blood (2015) 126 (23): 2753.
https://doi.org/10.1182/blood.V126.23.2753.2753
Published: 2015
Journal Articles

Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression

Adam M. Petrich, MD, Stefan Klaus Barta, MDMRCP,MS, Frederick Lansigan, MD, Trent Wang, MD, Ananta Bhatt, MD, Garrett Wasp, MD, Addie Hill, MD, Frank C. Passero, Jr., MD, Amrit Kahalon, MD, Roopesh R. Kansara, MD, Mitul Gandhi, MD, Graham W. Slack, MD, Tatyana Feldman, MD, Andrew M. Evens, DO, MSc, Kerry J. Savage, MDMSc
Journal: Blood
Blood (2015) 126 (23): 2737.
https://doi.org/10.1182/blood.V126.23.2737.2737
Published: 2015